# Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

> **NCT04156828** · PHASE1 · TERMINATED · sponsor: **University of Washington** · enrollment: 12 (actual)

## Conditions studied

- Grade 3b Follicular Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT04156828
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-31
- **Primary completion:** 2022-04-27
- **Final completion:** 2023-06-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Terminated due to low accrual
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156828, "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04156828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*